SOVREMENNYE PODKhODY K DIAGNOSTIKE I LEChENIYu OSTEOPOROZA
- Authors: Lesnyak O.M.1
-
Affiliations:
- Issue: No 2s (2012)
- Pages: 40-44
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279268
- ID: 279268
Cite item
Open Access
Access granted
Abstract
Osteoporosis is a common disease characterized by bone mass loss and impaired microarchitectonics of bone tissue, leading to bone fragility and a predisposition to bone fracture. Current strategy of the management of osteoporotic patients includes early diagnosis with the definition of high risk of fractures, and early use of pathogenetic treatment. Modern methods of assessment of fracture risk (osteodensitometry and FRAX calculator) allow accurately predicting the risk and early beginning appropriate treatment. The modern arsenal of pathogenetic therapy of osteoporosis consist of drugs with two main action - antiresorptive agents (bisphosphonates, deno-sumab - suppressing excess osteoclastic bone resorption) and anabolic agents (parathyroid hormone drugs stimulating bone formation by osteoblasts), as well as dual-action drugs (strontium ranelate).
Full Text
References
- Лесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Остеопороз и остеопатии. 2011. № 2. С. 3-6.
- Ершова О.Б. и др. В кн.: Остеопороз / Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд., перераб. и доп. М., 2011. 272 с. (Серия “Клинические рекомендации").
- Kanis J.A., Johnell O., De Laet C., et al. A metaanalysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375-82.
- Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures. BMJ 1996; 312(7041): 1254-59.
- Weinwright S.A., Marshall L.M., Ensrud K.E., et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90(5): 2787-93.
- Sanders K.M., Nicholson G.C., Watts J.J., et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 2006; 38(5): 694-700.
- Dimai H.P., Chandran M. On behalf of the FRAX Position Development Conference Members. Official Positions for FRAX Clinical Regarding Smoking. J Clin Densitom 2011; 14(3): 190-93.
Supplementary files
